# Alexandros Sagkriotis

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alexandros-sagkriotis/

## Facts

| Field | Value |
| --- | --- |
| Citations | 963 |
| Field | Retinal Diseases and Treatments |
| h-index | 14 |
| i10-index | 18 |
| Last Known Institution | Novartis (Switzerland) |
| OpenAlex ID | https://openalex.org/A5084337544 |
| ORCID iD | 0000-0002-1666-5248 |
| Works | 80 |

## Researcher papers

- [Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD](https://scholariq.org/papers/impact-of-macular-fluid-volume-fluctuations-on-visual-acuity-during-anti-vegf/)
- [Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD](https://scholariq.org/papers/comparison-of-a-combination-of-tiotropium-plus-formoterol-to-salmeterol-plus/)
- [Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics](https://scholariq.org/papers/serum-irisin-levels-are-lower-in-patients-with-breast-cancer-association-with/)
- [SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States](https://scholariq.org/papers/sierra-amd-a-retrospective-real-world-evidence-study-of-patients-with/)
- [Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration](https://scholariq.org/papers/association-between-visual-acuity-lesion-activity-markers-and-retreatment/)
- [Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA](https://scholariq.org/papers/treatment-frequency-and-dosing-interval-of-ranibizumab-and-aflibercept-for/)
- [Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study](https://scholariq.org/papers/treatment-patterns-and-persistence-rates-with-anti-vascular-endothelial-growth/)
- [Ranibizumab Prefilled Syringes: Benefits of Reduced Syringe Preparation Times and Less Complex Preparation Procedures](https://scholariq.org/papers/ranibizumab-prefilled-syringes-benefits-of-reduced-syringe-preparation-times-and/)
- [Soluble human leukocyte antigen-G expression in patients with ductal and lobular breast malignancy.](https://scholariq.org/papers/soluble-human-leukocyte-antigen-g-expression-in-patients-with-ductal-and-lobular/)
- [Social Media Listening to Understand the Lived Experience of Individuals in Europe With Metastatic Breast Cancer: A Systematic Search and Content Analysis Study](https://scholariq.org/papers/social-media-listening-to-understand-the-lived-experience-of-individuals-in/)
- [Bridging evidence worlds: policy and practice pathways for integrating clinical trials and real-world data in drug development and HTA](https://scholariq.org/papers/bridging-evidence-worlds-policy-and-practice-pathways-for-integrating-clinical/)

## Researcher topics

- [Retinal Diseases and Treatments](https://scholariq.org/topics/retinal-diseases-and-treatments/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Retinal Imaging and Analysis](https://scholariq.org/topics/retinal-imaging-and-analysis/)
- [Social Media in Health Education](https://scholariq.org/topics/social-media-in-health-education/)
- [Ophthalmology and Visual Impairment Studies](https://scholariq.org/topics/ophthalmology-and-visual-impairment-studies/)

## Researcher university

- [Novartis (Switzerland)](https://scholariq.org/institutions/novartis-switzerland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.